Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984650 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRKDM4ELMNAIDO1 | |
| SCHEMBL4980084 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRKDM4ELMNAIDO1 | |
| SCHEMBL5631914 | 0.89 | MEN1 (0.43) | SMN1; SMN2TSHRKDM4ELMNAIDO1 | |
| SCHEMBL5631906 | 0.89 | MEN1 (0.43) | SMN1; SMN2TSHRKDM4ELMNAIDO1 | |
| SCHEMBL14980211 | 0.88 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRKDM4ELMNACYP1A2 | |
| SCHEMBL5631816 | 0.88 | IDO1 (0.47) | SMN1; SMN2TSHRKDM4ELMNAIDO1 | |
| SCHEMBL5631811 | 0.88 | IDO1 (0.47) | SMN1; SMN2TSHRKDM4ELMNAIDO1 | |
| SCHEMBL5630943 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRKDM4ELMNAIDO1 | |
| SCHEMBL5630948 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRKDM4ELMNAIDO1 | |
| SCHEMBL5632217 | 0.85 | IDO1 (0.48) | SMN1; SMN2TSHRIDO1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951536-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-02-10 | — | — | US | claimed |
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2013-07-11 | — | — | US | claimed |
| EP-1971583-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2008-09-24 | — | — | EP | claimed |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-09 | — | — | US | claimed |
| WO-2007075598-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2007-07-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | SMN1; SMN2 3175/4885TSHR 2488/4885KDM4E 1275/4885 |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, HNMT | SMN1; SMN2 3175/4885TSHR 2488/4885KDM4E 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.